Tabimorelin
Also called NN703
Oral (by mouth)Human study reference
Research reference
Human study
NN703 seven-day study
Once daily in separate weight-based groups: 1.71, 3, 4.5 or 6.86 mg/kg
7 days
NN703 primary study (2001) ↗When results may show
- When change was measured
- GH response was measured on days 1 and 7; release decreased across that short interval. This is not evidence of sustained clinical benefit.
- When to assess
- 7 days
- Conditions and limitations
- Healthy adult men in a randomized placebo-controlled experiment. No fixed-dose starter or anti-aging course follows from weight-based hormone-response research. CYP3A4 interactions also require review.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Sources: NN703 primary study (2001)
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.02× single dose
- Time to steady state
- 20hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- NN703 primary study (2001)No fixed-dose starter or anti-aging course follows from weight-based hormone-response research. CYP3A4 interactions also require review.